alpha-helical polypeptide-messenger ribonucleic acid neoantigen vaccine

The alpha-helical polypeptide-messenger ribonucleic acid neoantigen vaccine is an experimental cancer immunotherapy platform that utilizes cationic α-helical polypeptides, specifically L-PPOB50-G, to deliver messenger RNA (mRNA) encoding tumor-specific neoantigens. This system is designed to overcome the limitations of traditional lipid nanoparticle (LNP) delivery by providing a self-adjuvanting effect. The polypeptide carrier facilitates the intracellular entry of mRNA into dendritic cells (DCs) via temporary membrane disruption and concurrently activates the NF-κB, IRF, and STING signaling pathways. This dual action promotes DC maturation and enhances the processing and presentation of neoantigens, eliciting a robust neoantigen-specific cytotoxic T lymphocyte (CTL) response. Preclinical data presented at AACR 2026 demonstrated significant tumor-free survival in models of lymphoma and triple-negative breast cancer, showing superior efficacy compared to conventional formulations and synergistic potential when combined with anti-PD-1 therapy.

Other names

α-helical polypeptide-mRNA polyplexL-PPOB50-G-mRNA vaccineL-PPOB-50-G-mRNA vaccineL-PPOB 50-G-mRNA vaccineself-adjuvanting α-helical polypeptide-mRNA vaccine